Reuters logo
BRIEF-Inovio, Apollobio to develop and commercialize hpv pre-cancer immunotherapy VGX-3100 in Greater China
February 13, 2017 / 11:20 AM / 10 months ago

BRIEF-Inovio, Apollobio to develop and commercialize hpv pre-cancer immunotherapy VGX-3100 in Greater China

Feb 13 (Reuters) - Inovio Pharmaceuticals Inc

* Inovio and Apollobio to collaborate on development and commercialization of hpv pre-cancer immunotherapy VGX-3100 in Greater China

* Inovio Pharmaceuticals Inc - Inovio will receive $15 million in upfront and near term payments comprising an initial $3 million signing fee

* Inovio Pharmaceuticals Inc - Inovio will receive a $12 million milestone upon lifting of VGX-3100 Phase 3 pre-initiation clinical hold by FDA

* Inovio Pharmaceuticals Inc - under a separate equity agreement, Apollobio will invest in Inovio common stock subsequent to lifting of clinical hold

* Inovio Pharmaceuticals Inc - aggregate investment, which is expected to be completed in first half of 2017, will not exceed $35 million

* Inovio Pharmaceuticals Inc - Apollobio will fund all clinical development costs within licensed territory, and will pay Inovio up to $20 million

* Inovio Pharma- agreements are subject to People’s Republic of China corporate and regulatory approvals, payments are subject to PRC currency approvals

* Inovio - payment of $20 million based upon achievement of certain regulatory milestones in U.S., China, Korea, double digit royalties on net sales of VGX-3100 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below